These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1564603)

  • 1. The impact of an i.v. team on the occurrence of intravenous-related phlebitis. A 30-month study.
    Scalley RD; Van CS; Cochran RS
    J Intraven Nurs; 1992; 15(2):100-9. PubMed ID: 1564603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of infusion-related phlebitis: review and nursing protocol.
    Perucca R; Micek J
    J Intraven Nurs; 1993; 16(5):282-6. PubMed ID: 8229430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in nosocomial intravenous device-related bacteremias after institution of an intravenous therapy team.
    Miller JM; Goetz AM; Squier C; Muder RR
    J Intraven Nurs; 1996; 19(2):103-6. PubMed ID: 8852171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postinfusion phlebitis after intravenous push versus intravenous piggyback administration of antimicrobial agents.
    Garrelts JC; Ast D; LaRocca J; Smith DF; Peterie JD
    Clin Pharm; 1988 Oct; 7(10):760-5. PubMed ID: 3233896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of inline filtration of intravenous infusions on the incidence of thrombophlebitis.
    Chamberland ME; Lyons RW; Brock SM
    Am J Hosp Pharm; 1977 Oct; 34(10):1068-70. PubMed ID: 920740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The benefits of an i.v. team in hospital practice.
    Dougherty L
    Prof Nurse; 1996 Aug; 11(11):761-3. PubMed ID: 8718322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous fluid therapy: a randomized controlled trial to investigate the effectiveness of the IV(2) flow medical device.
    Fraser N; Snyman JR; Wessels F; Nel G
    J Clin Nurs; 2007 Sep; 16(9):1593-601. PubMed ID: 17727580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downsizing. Use intravenous clinicians to maintain quality venous access care.
    Miller PK
    J Intraven Nurs; 1998; 21(2):105-12. PubMed ID: 9601318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Market your expertise for the changing future of intravenous therapy.
    Anderson D; Anderson C
    J Intraven Nurs; 1994; 17(6):291-8. PubMed ID: 7853113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of establishing an intravenous team and the standardization of peripheral intravenous catheters.
    da Silva GA; Priebe S; Dias FN
    J Infus Nurs; 2010; 33(3):156-60. PubMed ID: 20442599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of local i.v. complications and the method of intermittenti.v. access.
    Hunter ES; Bell E; Staub MA; Coyle G
    J Intraven Nurs; 1995; 18(4):202-6. PubMed ID: 7629641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Centralized i.v. team provides inpatient and home-care treatment.
    Christensen L; Greenough B
    Nurs Manage; 1998 Sep; 29(9):69-71. PubMed ID: 9807480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost savings approach for justification of an i.v. therapy team.
    Mendez-Lang M
    NITA; 1987; 10(5):348-56. PubMed ID: 3670713
    [No Abstract]   [Full Text] [Related]  

  • 14. The effects of utilization of an I.V. therapy team upon the incidence of I.V. peripheral-associated phlebitis.
    Trent BA
    NITA; 1984; 7(4):295-306. PubMed ID: 6565186
    [No Abstract]   [Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predisposing factors to phlebitis in patients with peripheral intravenous catheters: a descriptive study.
    Uslusoy E; Mete S
    J Am Acad Nurse Pract; 2008 Apr; 20(4):172-80. PubMed ID: 18387013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Justification for a pharmacy-coordinated I.V. therapy team.
    Kopp DL; Hammel RJ
    Hosp Pharm; 1978 Jul; 13(7):375-6, 378, 380 passim. PubMed ID: 10308297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nursing implications of low-dose heparin to infusate to improve infusion site survival in children.
    Wright A
    Aust Crit Care; 1993 Dec; 6(4):10-3. PubMed ID: 8136625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infusion-related phlebitis.
    Danchaivijitr S; Srihapol N; Pakaworawuth S; Vaithayapiches S; Judang T; Pumsuwan V; Kachintorn K
    J Med Assoc Thai; 1995 Jul; 78 Suppl 2():S85-90. PubMed ID: 7561602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I.v.-related phlebitis, complications and length of hospital stay: 1.
    Campbell L
    Br J Nurs; 1998 Nov 26-Dec 9; 7(21):1304-6, 1308-12. PubMed ID: 10076204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.